On Demand 2023 Thursday Program
You can earn up to 7.25 AMA PRA Category 1 Credit(s)TM.
Price: FREE for meeting attendees who purchased a ticket to the Thursday Program, otherwise $99 members, $125 non-members
This year’s Thursday Program will feature the latest developments in the science, diagnosis, and therapeutics for mast cell diseases and anaphylaxis.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical professionals who treat patients with allergic and/or immunological conditions:
- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Nurses and advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals
Upon completion of this session, participants should be able to:
- Identify receptors and signaling molecules in mast cells that can be targeted for therapeutics.
- Discuss novel insights into mechanisms of action for drug allergies.
- Describe the genetics of tryptase and how copy number variations in this gene can lead to clinical findings.
- Define current nomenclature for mast cell diseases.
- Review the differential diagnosis for patients with idiopathic anaphylaxis.
- Describe therapeutic options for patients with recurrent anaphylaxis and mast cell diseases.
- Develop a plan for formal diagnosis of alpha-gal allergy, including how best to perform oral challenges and how to manage patients with alpha-gal allergy in less common clinical scenarios, such as if they need a prosthetic valve.
- Recite and discuss risk factors for fatal anaphylaxis and incidence of fatal outcomes.
- Consider a risk-stratification model when diagnosing patients with food allergies.
- Review updates to the newest U.S. anaphylaxis practice parameters.
- Discuss data on the effect of epinephrine when administered to healthy controls as well as patients undergoing an allergic reaction and why it is recommended as first line therapy for anaphylaxis.
- Describe how to improve outcomes of anaphylaxis in the community setting and identify where anaphylaxis occurs in the community.
- Compare the current data on epinephrine when given by intranasal or sublingual route versus when given by intramuscular route.
Jay A. Lieberman, MD, FACAAI
Dana V. Wallace, MD, FACAAI
Lawrence B. Schwartz, MD, PhD, FACAAI
Marianna C. Castells, MD, PhD, FACAAI
Jonathan J. Lyons, MD
Joseph Butterfield, MD
Thomas A. E. Platts-Mills, MD, PhD, FACAAI
Matthew P. Giannetti, MD
Scott P. Commins, MD, PhD
Paul Turner, PhD
Matthew C. Greenhawt, MD, MBA, MSc, FACAAI
David BK Golden, MD, FACAAI
- 7.25 AMA PRA Category 1 Credit™
- 7.25 Attendance
- 7.25 CBRN